CoChat
Sign Up
Cited by 21

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Tissue-specific and exosomal miRNAs in lung cancer radiotherapy: from regulatory mechanisms to clinical implications

Long, Long, Zhang, Xue, Bai, Jian, Li, Yizhou, Wang, Xiaolong, Zhou, Yunfeng·2019·Cancer Management and Research
DOI 10.2147/cmar.s198966PMC PMC6525830
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/cmar.s198966

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 An overview of tissue-specific miRNAs in the regulation of lung cancer radiosensitivity.Notes: MiRNAs exert essential function to regulate the radiosensitivity of lung cancer cells, through complex interaction with multiple biological processes including DNA damage response, cell cycle and apoptosis, hypoxic tumor microenvironment, epithelial-mesenchymal transition, cancer stem cells and radiation-induced signaling pathways.
Figure 1 An overview of tissue-specific miRNAs in the regulation of lung cancer radiosensitivity.Notes: MiRNAs exert essential function to regulate the radiosensitivity of lung cancer cells, through complex interaction with multiple biological processes including DNA damage response, cell cycle and apoptosis, hypoxic tumor microenvironment, epithelial-mesenchymal transition, cancer stem cells and radiation-induced signaling pathways.CC BY-NC · PubMed Central
Figure 2 miRNAs in DNA-damage response, cell cycle, and apoptosis.Notes: Radiotherapy utilizes ionizing radiation to generate free radicals and intermediate ions, which damage tumor cells at different levels, especially with DNA double-strand breaks, initiating diverse signaling pathways to repair. Cyclins and CDKs are indispensable regulators of cell-cycle transition, which can be suppressed by checkpoints at G1/S and G2/M interphases, ultimately to arrest cell-cycle progression and allow enough time for DNA-damage repair. If DNA damage is too severe to repair, cells will proceed to apoptosis or programmed cell death.Abbreviations: IR, ionizing radiation; PKcs, PK catalytic subunits.
Figure 2 miRNAs in DNA-damage response, cell cycle, and apoptosis.Notes: Radiotherapy utilizes ionizing radiation to generate free radicals and intermediate ions, which damage tumor cells at different levels, especially with DNA double-strand breaks, initiating diverse signaling pathways to repair. Cyclins and CDKs are indispensable regulators of cell-cycle transition, which can be suppressed by checkpoints at G1/S and G2/M interphases, ultimately to arrest cell-cycle progression and allow enough time for DNA-damage repair. If DNA damage is too severe to repair, cells will proceed to apoptosis or programmed cell death.Abbreviations: IR, ionizing radiation; PKcs, PK catalytic subunits.CC BY-NC · PubMed Central
Figure 3 Exosomes and exosomal miRNAs in lung cancer therapy.Notes: Exosomes are small membrane–derived vesicles in circulating body fluids that are released by multiple cell types, including tumor cells and normal cells. Exosomes specialize in intracellular communication, via transporting diverse molecular constitutes. Exosomal cargoes are mainly small regulatory molecules, including miRNAs, mRNAs, DNA, and proteins. Among them, exosomal miRNAs may be promising in regulating cellular radiosensitivity and monitoring radiotherapy effectiveness.
Figure 3 Exosomes and exosomal miRNAs in lung cancer therapy.Notes: Exosomes are small membrane–derived vesicles in circulating body fluids that are released by multiple cell types, including tumor cells and normal cells. Exosomes specialize in intracellular communication, via transporting diverse molecular constitutes. Exosomal cargoes are mainly small regulatory molecules, including miRNAs, mRNAs, DNA, and proteins. Among them, exosomal miRNAs may be promising in regulating cellular radiosensitivity and monitoring radiotherapy effectiveness.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 83

  1. [1]Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1): 7– 30. doi: 10.3322/caac.21442 29313949 · DOI
  2. [2]Travis WD, Brambilla E, Nicholson AG, et al. The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015; 10(9): 1243– 1260. doi: 10.1097/JTO.0000000000000630 26291008 · DOI
  3. [3]Lischalk JW, Woo SM, Kataria S, et al. Long-term outcomes of stereotactic body radiation therapy (SBRT) with fiducial tracking for inoperable stage I non-small cell lung cancer (NSCLC). J Radiat Oncol. 2016; 5(4): 379– 387. doi: 10.1007/s13566-016-0273-4 28018523 PMC5149392 · DOI
  4. [4]Willers H, Azzoli CG, Santivasi WL, Xia F. Basic mechanisms of therapeutic resistance to radiation and chemotherapy in lung cancer. Cancer J. 2013; 19(3): 200– 207. doi: 10.1097/PPO.0b013e318292e4e3 23708066 PMC3668666 · DOI
  5. [5]Rosenzweig KE, Gomez JE. Concurrent chemotherapy and radiation therapy for inoperable locally advanced non-small-cell lung cancer. J Clin Oncol. 2017; 35(1): 6– 10. doi: 10.1200/JCO.2016.69.9678 27870565 · DOI
  6. [6]Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2): 281– 297. 14744438
  7. [7]Czochor JR, Glazer PM. microRNAs in cancer cell response to ionizing radiation. Antioxid Redox Signal. 2014; 21(2): 293– 312. doi: 10.1089/ars.2013.5718 24206455 PMC4066235 · DOI
  8. [8]Sun Y, Hawkins PG, Bi N, et al. Serum microRNA signature predicts response to high-dose radiation therapy in locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2018; 100(1): 107– 114. doi: 10.1016/j.ijrobp.2017.08.039 29051037 PMC5736451 · DOI
  9. [9]Malla B, Zaugg K, Vassella E, Aebersold DM, Dal Pra A. Exosomes and exosomal MicroRNAs in prostate cancer radiation therapy. Int J Radiat Oncol Biol Phys. 2017; 98(5): 982– 995. doi: 10.1016/j.ijrobp.2017.03.031 28721912 · DOI
  10. [10]Vanni I, Alama A, Grossi F, Dal Bello MG, Coco S. Exosomes: a new horizon in lung cancer. Drug Discov Today. 2017; 22(6): 927– 936. doi: 10.1016/j.drudis.2017.03.004 28288782 · DOI
  11. [11]Tang Y, Cui Y, Li Z, et al. Radiation-induced miR-208a increases the proliferation and radioresistance by targeting p21 in human lung cancer cells. J Exp Clin Cancer Res. 2016; 35: 7. doi: 10.1186/s13046-016-0444-6 26754670 PMC4710038 · DOI
  12. [12]Li L, Story M, Legerski RJ. Cellular responses to ionizing radiation damage. Int J Radiat Oncol Biol Phys. 2001; 49(4): 1157– 1162. 11240259
  13. [13]Hu H, Gatti RA. MicroRNAs: new players in the DNA damage response. J Mol Cell Biol. 2011; 3(3): 151– 158. doi: 10.1093/jmcb/mjq042 21183529 PMC3104011 · DOI
  14. [14]Ma W, Ma CN, Zhou NN, Li XD, Zhang YJ. Up- regulation of miR-328-3p sensitizes non-small cell lung cancer to radiotherapy. Sci Rep. 2016; 6: 31651. doi: 10.1038/srep31651 27530148 PMC4987701 · DOI
  15. [15]Guo Y, Sun W, Gong T, et al. miR-30a radiosensitizes non-small cell lung cancer by targeting ATF1 that is involved in the phosphorylation of ATM. Oncol Rep. 2017; 37(4): 1980– 1988. doi: 10.3892/or.2017.5448 28259977 PMC5367375 · DOI
  16. [16]Chen S, Wang H, Ng WL, Curran WJ, Wang Y. Radiosensitizing effects of ectopic miR-101 on non-small-cell lung cancer cells depend on the endogenous miR-101 level. Int J Radiat Oncol Biol Phys. 2011; 81(5): 1524– 1529. doi: 10.1016/j.ijrobp.2011.05.031 22014955 · DOI
  17. [17]Li Y, Han W, Ni TT, et al. Knockdown of microRNA-1323 restores sensitivity to radiation by suppression of PRKDC activity in radiation-resistant lung cancer cells. Oncol Rep. 2015; 33(6): 2821– 2828. doi: 10.3892/or.2015.3884 25823795 · DOI
  18. [18]Cortez MA, Valdecanas D, Niknam S, et al. In vivo delivery of miR-34a sensitizes lung tumors to radiation through RAD51 regulation. Mol Ther Nucleic Acids. 2015; 4: e270. doi: 10.1038/mtna.2015.47 26670277 PMC5014539 · DOI
  19. [19]Medema RH, Macurek L. Checkpoint control and cancer. Oncogene. 2012; 31(21): 2601– 2613. doi: 10.1038/onc.2011.451 21963855 · DOI
  20. [20]Liu Q, Fu H, Sun F, et al. miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res. 2008; 36(16): 5391– 5404. doi: 10.1093/nar/gkn522 18701644 PMC2532718 · DOI
  21. [21]Rahmanian N, Hosseinimehr SJ, Khalaj A. The paradox role of caspase cascade in ionizing radiation therapy. J Biomed Sci. 2016; 23(1): 88. doi: 10.1186/s12929-016-0306-8 27923354 PMC5142153 · DOI
  22. [22]He Z, Liu Y, Xiao B, Qian X. miR-25 modulates NSCLC cell radio-sensitivity through directly inhibiting BTG2 expression. Biochem Biophys Res Commun. 2015; 457(3): 235– 241. doi: 10.1016/j.bbrc.2014.12.094 25576360 · DOI
  23. [23]Zhao L, Bode AM, Cao Y, Dong Z. Regulatory mechanisms and clinical perspectives of miRNA in tumor radiosensitivity. Carcinogenesis. 2012; 33(11): 2220– 2227. doi: 10.1093/carcin/bgs235 22798379 PMC3483015 · DOI
  24. [24]Arechaga-Ocampo E, Lopez-Camarillo C, Villegas-Sepulveda N, et al. Tumor suppressor miR-29c regulates radioresistance in lung cancer cells. Tumour Biol. 2017; 39(3). 1010428317695010. doi: 10.1177/1010428317695010 28345453 · DOI
  25. [25]Ma D, Jia H, Qin M, et al. MiR-122 induces radiosensitization in non-small cell lung cancer cell line. Int J Mol Sci. 2015; 16(9): 22137– 22150. doi: 10.3390/ijms160922137 26389880 PMC4613300 · DOI
  26. [26]Zhang HH, Pang M, Dong W, et al. miR-511 induces the apoptosis of radioresistant lung adenocarcinoma cells by triggering BAX. Oncol Rep. 2014; 31(3): 1473– 1479. doi: 10.3892/or.2014.2973 24402374 · DOI
  27. [27]Ma W, Ma CN, Li XD, Zhang YJ. Examining the effect of gene reduction in miR-95 and enhanced radiosensitivity in non-small cell lung cancer. Cancer Gene Ther. 2016; 23(2–3): 66– 71. doi: 10.1038/cgt.2016.2 26915403 · DOI
  28. [28]Wang M, Meng B, Liu Y, Yu J, Chen Q, Liu Y. MiR-124 inhibits growth and enhances radiation-induced apoptosis in non-small cell lung cancer by inhibiting STAT3. Cell Physiol Biochem. 2017; 44(5): 2017– 2028. doi: 10.1159/000485907 29237164 · DOI
  29. [29]Zhu L, Xue F, Xu X, et al. MicroRNA-198 inhibition of HGF/c-MET signaling pathway overcomes resistance to radiotherapy and induces apoptosis in human non-small-cell lung cancer. J Cell Biochem. 2018;119(9):7873–7886. 29943841
  30. [30]Osinsky S, Zavelevich M, Vaupel P. Tumor hypoxia and malignant progression. Exp Oncol. 2009; 31(2): 80– 86. 19550396
  31. [31]Marignol L, Coffey M, Lawler M, Hollywood D. Hypoxia in prostate cancer: a powerful shield against tumour destruction? Cancer Treat Rev. 2008; 34(4): 313– 327. doi: 10.1016/j.ctrv.2008.01.006 18334284 · DOI
  32. [33]Meijer TW, Kaanders JH, Span PN, Bussink J. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res. 2012; 18(20): 5585– 5594. doi: 10.1158/1078-0432.CCR-12-0858 23071360 · DOI · Paper page
  33. [34]Jiang S, Wang R, Yan H, Jin L, Dou X, Chen D. MicroRNA-21 modulates radiation resistance through upregulation of hypoxia-inducible factor-1alpha-promoted glycolysis in non-small cell lung cancer cells. Mol Med Rep. 2016; 13(5): 4101– 4107. doi: 10.3892/mmr.2016.5010 27035555 · DOI
  34. [35]Grosso S, Doyen J, Parks SK, et al. MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines. Cell Death Dis. 2013; 4: e544. doi: 10.1038/cddis.2013.71 23492775 PMC3615727 · DOI
  35. [36]Marie-Egyptienne DT, Lohse I, Hill RP. Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia. Cancer Lett. 2013; 341(1): 63– 72. doi: 10.1016/j.canlet.2012.11.019 23200673 · DOI
  36. [37]Zhang Y, Zheng L, Huang J, et al. MiR-124 Radiosensitizes human colorectal cancer cells by targeting PRRX1. PLoS One. 2014; 9(4): e93917. doi: 10.1371/journal.pone.0093917 24705396 PMC3976353 · DOI
  37. [38]Luo H, Liang C. MicroRNA-148b inhibits proliferation and the epithelial-mesenchymal transition and increases radiosensitivity in non-small cell lung carcinomas by regulating ROCK1. Exp Ther Med. 2018; 15(4): 3609– 3616. doi: 10.3892/etm.2018.5845 29545890 PMC5840962 · DOI
  38. [39]Koo T, Cho BJ, Kim DH, et al. MicroRNA-200c increases radiosensitivity of human cancer cells with activated EGFR-associated signaling. Oncotarget. 2017; 8(39): 65457– 65468. doi: 10.18632/oncotarget.18924 29029445 PMC5630345 · DOI
  39. [40]Pajonk F, Vlashi E, McBride WH. Radiation resistance of cancer stem cells: the 4 R‘s of radiobiology revisited. Stem Cells. 2010; 28(4): 639– 648. doi: 10.1002/stem.318 20135685 PMC2940232 · DOI
  40. [41]Chiou GY, Cherng JY, Hsu HS, et al. Cationic polyurethanes-short branch PEI-mediated delivery of Mir145 inhibited epithelial-mesenchymal transdifferentiation and cancer stem-like properties and in lung adenocarcinoma. J Control Release. 2012; 159(2): 240– 250. doi: 10.1016/j.jconrel.2012.01.014 22285547 · DOI
  41. [42]Zhang J, Zhang C, Hu L, et al. Abnormal Expression of miR-21 and miR-95 in Cancer Stem-Like Cells is Associated with Radioresistance of Lung Cancer. Cancer Invest. 2015; 33(5): 165– 171. doi: 10.3109/07357907.2015.1019676 25831148 · DOI
  42. [43]Chen X, Wu L, Li D, et al. Radiosensitizing effects of miR-18a-5p on lung cancer stem-like cells via downregulating both ATM and HIF-1alpha. Cancer Med. 2018; 7(8): 3834– 3847. doi: 10.1002/cam4.1527 29860718 PMC6089184 · DOI
  43. [44]Korpela E, Vesprini D, Liu SK. MicroRNA in radiotherapy: miRage or miRador? Br J Cancer. 2015; 112(5): 777– 782. doi: 10.1038/bjc.2015.6 25611301 PMC4453960 · DOI
  44. [45]Guo Y, Jiang Y, Sang M, Xu C. Down-regulation of miR-373 increases the radiosensitivity of lung cancer cells by targeting TIMP2. Int J Biochem Cell Biol. 2018; 99: 203– 210. doi: 10.1016/j.biocel.2018.04.014 29673878 · DOI
  45. [46]Wang XC, Du LQ, Tian LL, et al. Expression and function of miRNA in postoperative radiotherapy sensitive and resistant patients of non-small cell lung cancer. Lung Cancer. 2011; 72(1): 92– 99. doi: 10.1016/j.lungcan.2010.07.014 20728239 · DOI
  46. [47]Tian F, Han Y, Yan X, et al. Upregulation of microrna-451 increases the sensitivity of A549 cells to radiotherapy through enhancement of apoptosis. Thorac Cancer. 2016; 7(2): 226– 231. doi: 10.1111/1759-7714.12318 27042226 PMC4773304 · DOI
  47. [48]Yin H, Ma J, Chen L, et al. MiR-99a enhances the radiation sensitivity of non-small cell lung cancer by targeting mTOR. Cell Physiol Biochem. 2018; 46(2): 471– 481. doi: 10.1159/000488615 29614485 · DOI
  48. [49]Jiang Y, Chen X, Tian W, Yin X, Wang J, Yang H. The role of TGF-beta1-miR-21-ROS pathway in bystander responses induced by irradiated non-small-cell lung cancer cells. Br J Cancer. 2014; 111(4): 772– 780. doi: 10.1038/bjc.2014.368 24992582 PMC4134503 · DOI
  49. [50]Xiong K, Shao LH, Zhang HQ, et al. MicroRNA-9 functions as a tumor suppressor and enhances radio-sensitivity in radio-resistant A549 cells by targeting neuropilin 1. Oncol Lett. 2018; 15(3): 2863– 2870. doi: 10.3892/ol.2017.7705 29435012 PMC5778782 · DOI
  50. [51]Arora H, Qureshi R, Jin S, Park AK, Park WY. miR-9 and let-7g enhance the sensitivity to ionizing radiation by suppression of NFkappaB1. Exp Mol Med. 2011; 43(5): 298– 304. doi: 10.3858/emm.2011.43.5.031 21464588 PMC3104252 · DOI
  51. [52]Lan F, Yue X, Ren G, et al. miR-15a/16 enhances radiation sensitivity of non-small cell lung cancer cells by targeting the TLR1/NF-kappaB signaling pathway. Int J Radiat Oncol Biol Phys. 2015; 91(1): 73– 81. doi: 10.1016/j.ijrobp.2014.09.021 25442346 · DOI
  52. [53]Oh JS, Kim JJ, Byun JY, Kim IA. Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras. Int J Radiat Oncol Biol Phys. 2010; 76(1): 5– 8. doi: 10.1016/j.ijrobp.2009.08.028 20005451 · DOI
  53. [54]Wang Y, Scheiber MN, Neumann C, Calin GA, Zhou D. MicroRNA regulation of ionizing radiation-induced premature senescence. Int J Radiat Oncol Biol Phys. 2011; 81(3): 839– 848. doi: 10.1016/j.ijrobp.2010.09.048 21093163 PMC3056910 · DOI
  54. [55]Salim H, Akbar NS, Zong D, et al. miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence. Br J Cancer. 2012; 107(8): 1361– 1373. doi: 10.1038/bjc.2012.382 22929890 PMC3494421 · DOI
  55. [56]Weber JA, Baxter DH, Zhang S, et al. The microRNA spectrum in 12 body fluids. Clin Chem. 2010; 56(11): 1733– 1741. doi: 10.1373/clinchem.2010.147405 20847327 PMC4846276 · DOI · Paper page
  56. [57]Chen X, Liang H, Zhang J, Zen K, Zhang CY. Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol. 2012; 22(3): 125– 132. doi: 10.1016/j.tcb.2011.12.001 22260888 · DOI · Paper page
  57. [58]Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007; 9(6): 654– 659. doi: 10.1038/ncb1596 17486113 · DOI · Paper page
  58. [59]Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, et al. Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci U S A. 2010; 107(14): 6328– 6333. doi: 10.1073/pnas.0914843107 20304794 PMC2851954 · DOI
  59. [60]Templin T, Amundson SA, Brenner DJ, Smilenov LB. Whole mouse blood microRNA as biomarkers for exposure to gamma-rays and (56)Fe ion. Int J Radiat Biol. 2011; 87(7): 653– 662. doi: 10.3109/09553002.2010.549537 21271940 PMC3586327 · DOI
  60. [61]Templin T, Paul S, Amundson SA, et al. Radiation-induced micro-RNA expression changes in peripheral blood cells of radiotherapy patients. Int J Radiat Oncol Biol Phys. 2011; 80(2): 549– 557. doi: 10.1016/j.ijrobp.2010.12.061 21420249 PMC3589812 · DOI
  61. [62]Prise KM, O‘Sullivan JM. Radiation-induced bystander signalling in cancer therapy. Nat Rev Cancer. 2009; 9(5): 351– 360. doi: 10.1038/nrc2603 19377507 PMC2855954 · DOI
  62. [63]Yuan D, Xu J, Wang J, et al. Extracellular miR-1246 promotes lung cancer cell proliferation and enhances radioresistance by directly targeting DR5. Oncotarget. 2016; 7(22): 32707– 32722. doi: 10.18632/oncotarget.9017 27129166 PMC5078045 · DOI · Paper page
  63. [64]Dinh TK, Fendler W, Chalubinska-Fendler J, et al. Circulating miR-29a and miR-150 correlate with delivered dose during thoracic radiation therapy for non-small cell lung cancer. Radiat Oncol. 2016; 11: 61. doi: 10.1186/s13014-016-0636-4 27117590 PMC4847218 · DOI
  64. [65]Urbanelli L, Magini A, Buratta S, et al. Signaling pathways in exosomes biogenesis, secretion and fate. Genes (Basel). 2013; 4(2): 152– 170. doi: 10.3390/genes4020152 24705158 PMC3899971 · DOI
  65. [66]Cui S, Cheng Z, Qin W, Jiang L. Exosomes as a liquid biopsy for lung cancer. Lung Cancer. 2018; 116: 46– 54. doi: 10.1016/j.lungcan.2017.12.012 29413050 · DOI
  66. [67]Liu Y, Luo F, Wang B, et al. STAT3-regulated exosomal miR-21 promotes angiogenesis and is involved in neoplastic processes of transformed human bronchial epithelial cells. Cancer Lett. 2016; 370(1): 125– 135. doi: 10.1016/j.canlet.2015.10.011 26525579 · DOI
  67. [68]Hsu YL, Hung JY, Chang WA, et al. Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1. Oncogene. 2017; 36(34): 4929– 4942. doi: 10.1038/onc.2017.105 28436951 · DOI
  68. [69]Cui H, Seubert B, Stahl E, et al. Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes. Oncogene. 2015; 34(28): 3640– 3650. doi: 10.1038/onc.2014.300 25263437 · DOI
  69. [70]Kim J, Kim TY, Lee MS, Mun JY, Ihm C, Kim SA. Exosome cargo reflects TGF-beta1-mediated epithelial-to-mesenchymal transition (EMT) status in A549 human lung adenocarcinoma cells. Biochem Biophys Res Commun. 2016; 478(2): 643– 648. doi: 10.1016/j.bbrc.2016.07.124 27492069 · DOI
  70. [71]Wu H, Zhou J, Mei S, et al. Circulating exosomal microRNA-96 promotes cell proliferation, migration and drug resistance by targeting LMO7. J Cell Mol Med. 2017; 21(6): 1228– 1236. doi: 10.1111/jcmm.13056 28026121 PMC5431139 · DOI
  71. [72]Adi Harel S, Bossel Ben-Moshe N, Aylon Y, et al. Reactivation of epigenetically silenced miR-512 and miR-373 sensitizes lung cancer cells to cisplatin and restricts tumor growth. Cell Death Differ. 2015; 22(8): 1328– 1340. doi: 10.1038/cdd.2014.221 25591738 PMC4495356 · DOI
  72. [73]Yuwen DL, Sheng BB, Liu J, Wenyu W, Shu YQ. MiR-146a-5p level in serum exosomes predicts therapeutic effect of cisplatin in non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 2017; 21(11): 2650– 2658. 28678319
  73. [74]Yang M, Shen H, Qiu C, et al. High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. Eur J Cancer. 2013; 49(3): 604– 615. doi: 10.1016/j.ejca.2012.09.031 23099007 · DOI
  74. [75]Rabinowits G, Gercel-Taylor C, Day JM, Taylor DD, Kloecker GH. Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer. 2009; 10(1): 42– 46. doi: 10.3816/CLC.2009.n.006 19289371 · DOI
  75. [76]Jin X, Chen Y, Chen H, et al. Evaluation of tumor-derived exosomal mirna as potential diagnostic biomarkers for early-stage non-small cell lung cancer using next-generation sequencing. Clin Cancer Res. 2017; 23(17): 5311– 5319. doi: 10.1158/1078-0432.CCR-17-0577 28606918 · DOI
  76. [77]Mutschelknaus L, Peters C, Winkler K, et al. Exosomes derived from squamous head and neck cancer promote cell survival after ionizing radiation. PLoS One. 2016; 11(3): e0152213. doi: 10.1371/journal.pone.0152213 27006994 PMC4805173 · DOI
  77. [78]Boelens MC, Wu TJ, Nabet BY, et al. Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. Cell. 2014; 159(3): 499– 513. doi: 10.1016/j.cell.2014.09.051 25417103 PMC4283810 · DOI
  78. [79]Cai S, Shi GS, Cheng HY, et al. Exosomal miR-7 mediates bystander autophagy in lung after focal brain irradiation in mice. Int J Biol Sci. 2017; 13(10): 1287– 1296. doi: 10.7150/ijbs.18890 29104495 PMC5666527 · DOI
  79. [80]Wang R, Ye F, Zhen Q, et al. MicroRNA-148b is a potential prognostic biomarker and predictor of response to radiotherapy in non-small-cell lung cancer. J Physiol Biochem. 2016; 72(2): 337– 343. doi: 10.1007/s13105-016-0485-5 27083571 · DOI
  80. [81]Xie P, Li X, Tan X, Sun X, Wang C, Yu J. Sequential serum let-7 is a novel biomarker to predict accelerated reproliferation during fractional radiotherapy in lung cancer. Clin Lung Cancer. 2016; 17(5): e95– e101. doi: 10.1016/j.cllc.2016.03.010 27133539 · DOI
  81. [82]Xu T, Liao Z, O‘Reilly MS, et al. Serum inflammatory miRNAs predict radiation esophagitis in patients receiving definitive radiochemotherapy for non-small cell lung cancer. Radiother Oncol. 2014; 113(3): 379– 384. doi: 10.1016/j.radonc.2014.11.006 25466375 · DOI
  82. [83]Florczuk M, Szpechcinski A, Chorostowska-Wynimko J. miRNAs as biomarkers and therapeutic targets in non-small cell lung cancer: current perspectives. Target Oncol. 2017; 12(2): 179– 200. doi: 10.1007/s11523-017-0478-5 28243959 · DOI
  83. [84]Iqbal MA, Arora S, Prakasam G, Calin GA, Syed MA. MicroRNA in lung cancer: role, mechanisms, pathways and therapeutic relevance. Mol Aspects Med. 2018. doi: 10.1016/j.mam.2018.07.003 30102929 · DOI

Cited by

Sorted by citations

Metadata

Authors
Long, L., Zhang, X., Bai, J., Li, Y., Wang, X., & Zhou, Y.
Venue
Cancer Management and Research
Publisher
Informa UK Limited
Published
2019-05
Volume
Volume 11
Pages
4413-4424
ISSN
1179-1322
DOI
10.2147/cmar.s198966
PMC
PMC6525830
Cited by
21
References
1
Language
en
Licence
creativecommons.org/licenses/by-nc/3.0/ (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review